Takeda Pharmaceutical (TAK) Profit After Tax (2017 - 2026)

Takeda Pharmaceutical has reported Profit After Tax for 10 years, with the latest figure at $710.6 million in Q2 2026.

• On a quarterly basis, Profit After Tax fell 17.27% year-over-year to $710.6 million in Q2 2026; TTM through Jun 2026 was $577.3 million, a 76.06% decrease from a year earlier, with the FY2026 full-year figure at -$970.0 million, down 236.64% from the prior year.
• Profit After Tax was $710.6 million for Q2 2026 at Takeda Pharmaceutical, down from $792.6 million in the prior quarter.
• The five-year high for Profit After Tax was $2.0 billion in Q3 2023, with the low at -$2.4 billion in Q4 2025.
• Average Profit After Tax over 5 years is $620.4 million, with a median of $793.2 million recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Profit After Tax jumped 342.91% in 2023, then slumped 422.33% in 2024.
• Over 5 years, Profit After Tax stood at $843.4 million in 2022, then plunged by 75.05% to $210.4 million in 2023, then tumbled by 422.33% to -$678.2 million in 2024, then slumped by 252.98% to -$2.4 billion in 2025, then soared by 129.68% to $710.6 million in 2026.
• The last three Profit After Tax figures came in at $710.6 million (Q2 2026), $792.6 million (Q1 2026), and -$2.4 billion (Q4 2025), per Business Quant data.